Metabolex, Inc. Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat
12/8/2011 7:19:24 AM
More...
|
Metabolex, Inc. Gout Program Recognized in Windhover's Top 10 Most Interesting Projects to Watch
11/29/2011 12:22:32 PM
More...
|
Metabolex, Inc. to Present Data on Arhalofenate, a Potential Novel Treatment for Gout, at the 2011ACR/ARHP Annual Scientific Meeting
11/1/2011 10:43:57 AM
More...
|
Metabolex, Inc. Appoints Raymond Urbanski M.D., Ph.D. to Position of Chief Medical Officer
10/20/2011 11:29:40 AM
More...
|
Metabolex, Inc. Initiates Phase 2 Trial of Arhalofenate
5/19/2011 9:00:36 AM
More...
|
Sanofi-Aventis (France) (SASY.PA) Opts Out of Metabolex, Inc. Diabetes Drug Deal; Deal Could Have Been Worth up to $375 Million
5/6/2011 7:24:55 AM
More...
|
Metabolex, Inc. to Conduct a Webcast of Its Second Quarter 2010 Earnings Call
7/16/2010 10:14:16 AM
More...
|
Sanofi-Aventis (France) (SASY.PA) Inks $375 Million Diabetes Deal With Metabolex, Inc.
6/25/2010 6:53:18 AM
More...
|
Metabolex, Inc. Enters Into Type 2 Diabetes Development and License Agreement with Ortho-McNeil Pharmaceutical, Inc.; Metabolex Could be Eligible to Receive Development, Regulatory, and Commercial Milestones up to $330 Million
6/22/2010 7:15:21 AM
More...
|
Metabolex, Inc. Initiates Research Collaboration with Takeda Pharmaceutical Co. Ltd. (TKDG.DE)
4/13/2010 9:19:26 AM
More...
|
|